The Goldman Sachs Group Issues Pessimistic Forecast for Cytek Biosciences (NASDAQ:CTKB) Stock Price
Cytek Biosciences (NASDAQ:CTKB – Get Free Report) had its price objective reduced by equities researchers at The Goldman Sachs Group from $3.50 to $3.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “sell” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 0.67% […]
Cytek Biosciences (NASDAQ:CTKB – Get Free Report) had its price objective reduced by equities researchers at The Goldman Sachs Group from $3.50 to $3.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “sell” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 0.67% […]
